Obefazimod Shows 'Meaningful Clinical Benefit' in Refractory UC Patients, Strengthens Phase 3 Safety Data
ABVX has more than doubled off its 52-week low of $7.24.
Summary
Abivax announced strong positive results from Part 2 of its Phase 3 ABTECT maintenance trial for obefazimod, demonstrating meaningful clinical benefit in highly refractory ulcerative colitis patients. Specifically, 37.2% of induction non-responders achieved clinical remission and 34.5% achieved endoscopic remission. This data significantly strengthens the long-term safety database and builds upon the highly positive topline results from the ABTECT maintenance trial reported earlier in June. The company is preparing for a planned NDA submission later this year, and these results reinforce the drug's potential as a paradigm-defining treatment.
At the time of this announcement, ABVX was trading at $96.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7B. The 52-week trading range was $7.24 to $148.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.